Sanofi - Company Profile
Powered by 
All the data and insights you need on Sanofi in one report.
$295
- Save hours of research time and resources with
our up-to-date Sanofi Strategy Report
- Understand Sanofi position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreSanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi's R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, Ile-de-France, France.
Headquarters
France
Address
46 Avenue De La Grande Armee, Paris, Ile-de-France, 75017
Website
www.sanofi.com
Telephone
33 1 53774000
No of Employees
87,994
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SAN (EPA)
Revenue (2022)
$50.2B
2.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-35.5%
(2022 vs 2021)
Market Cap*
$116.4B
Net Profit Margin (2022)
XYZ
-36.9%
(2022 vs 2021)
* As of and is in US$
Sanofi premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | Dupixent |
| Specialty Care: | Aubagio |
| Atopic Dermatitis | Lemtrada |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Plans/Strategy | In April, the company announced its plans to introduce 1 or 2 products every year from its innovation portfolio in India. |
| 2024 | Contracts/Agreements | In April, Opella Healthcare entered into a partnership with Phoenix to distribute the OTC products. |
| 2024 | New Products/Services | In April, the company launched Verorab in the UK. |
Competitor Comparison
| Key Parameters | Sanofi | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | France | United States of America | Switzerland | United States of America | United States of America |
| City | Paris | New Brunswick | Basel | Kenilworth | New York |
| State/Province | Ile-de-France | New Jersey | - | New Jersey | New York |
| No. of Employees | 87,994 | 131,900 | 103,605 | 72,000 | 88,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul Hudson | Director; Chief Executive Officer | Executive Board | 2019 | 55 |
| Jean-Baptiste Chasseloup de Chatillon | Chief Financial Officer; Executive Vice President | Senior Management | 2018 | 58 |
| Natalie Bickford | Chief People Officer; Executive Vice President | Senior Management | 2020 | 53 |
| Emmanuel Frenehard | Chief Digital Officer | Senior Management | 2023 | - |
| Frederic Oudea | Chairman | Non Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward